These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 10430061

  • 1. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG.
    Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
    [Abstract] [Full Text] [Related]

  • 2. Temozolomide and cisplatin in avdanced malignant melanoma.
    Daponte A, Ascierto PA, Gravina A, Melucci M, Scala S, Ottaiano A, Simeone E, Palmieris G, Comella G.
    Anticancer Res; 2005 Jul; 25(2B):1441-7. PubMed ID: 15865103
    [Abstract] [Full Text] [Related]

  • 3. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
    Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR, Rinaldi DA, Von Hoff DD, Rowinsky EK.
    J Clin Oncol; 1999 Aug; 17(8):2604-13. PubMed ID: 10561328
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ.
    Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
    [Abstract] [Full Text] [Related]

  • 5. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Jul; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ.
    Cancer Res; 1998 Oct 01; 58(19):4363-7. PubMed ID: 9766665
    [Abstract] [Full Text] [Related]

  • 7. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
    Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Briassoulis E, Efstathiou E, Polyzos A, Fountzilas G, Christodoulou C, Kouroussis C, Iconomou T, Gogas H.
    Ann Oncol; 2005 Jun 01; 16(6):950-7. PubMed ID: 15829494
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
    Silvani A, Eoli M, Salmaggi A, Lamperti E, Maccagnano E, Broggi G, Boiardi A.
    J Neurooncol; 2004 Jan 01; 66(1-2):203-8. PubMed ID: 15015788
    [Abstract] [Full Text] [Related]

  • 9. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
    Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M, Klouvas G, Skarlos D, Hellenic Cooperative Oncology Group.
    J Neurooncol; 2005 Jan 01; 71(1):61-5. PubMed ID: 15719277
    [Abstract] [Full Text] [Related]

  • 10. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
    Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE, Dugan M, Cutler D, Batra V, Grochow LB, Donehower RC, Rowinsky EK.
    Clin Cancer Res; 1999 Feb 01; 5(2):309-17. PubMed ID: 10037179
    [Abstract] [Full Text] [Related]

  • 11. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
    Warren KE, Aikin AA, Libucha M, Widemann BC, Fox E, Packer RJ, Balis FM.
    J Clin Oncol; 2005 Oct 20; 23(30):7646-53. PubMed ID: 16234526
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
    Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML.
    Clin Cancer Res; 2008 Dec 01; 14(23):7947-55. PubMed ID: 19047127
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
    Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, Lejeune F.
    Cancer Chemother Pharmacol; 1998 Dec 01; 42(6):433-40. PubMed ID: 9788568
    [Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
    Ricart AD, Hammond LA, Kuhn JG, Takimoto CH, Goetz A, Forouzesh B, Forero L, Ochoa-Bayona JL, Berg K, Tolcher AW, Rowinsky EK.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8728-36. PubMed ID: 16361560
    [Abstract] [Full Text] [Related]

  • 16. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS, Kirkwood JM.
    Cancer; 2003 Jan 01; 97(1):121-7. PubMed ID: 12491513
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
    Riccardi A, Mazzarella G, Cefalo G, Garrè ML, Massimino M, Barone C, Sandri A, Ridola V, Ruggiero A, Mastrangelo S, Lazzareschi I, Caldarelli M, Maira G, Madon E, Riccardi R.
    Cancer Chemother Pharmacol; 2003 Dec 01; 52(6):459-64. PubMed ID: 13680160
    [Abstract] [Full Text] [Related]

  • 20. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
    Kobayashi K, Shinbara A, Kamimura M, Takeda Y, Kudo K, Kabe J, Hibino S, Hino M, Shibuya M, Kudoh S.
    Cancer Chemother Pharmacol; 1998 Dec 01; 42(1):53-8. PubMed ID: 9619758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.